Citations

Clear

1792 citation(s) found for "Stephanie".

The Outcomes of Surgical Pulmonary Embolectomy for Pulmonary Embolism: A Meta-Analysis
Rahouma, Mohamed , Al-Thani, Shaikha, Salem, Haitham , Mahmoud, Alzahraa, Khairallah, Sherif , Shenouda, David, Sultan, Batool, Khalil, Leen A. , Alomari, Mohammad , Ali, Mostafa, Makey, Ian A. , Haney, John C. , Mick, Stephanie, Ahmed, Magdy M. El‐Sayed , Khalil, Laila , Haney, John , Rahouma, Mohammed

Mayo Clinic

Journal of Clinical Medicine | July 12, 2024 | Volume: 13 | Issue: 14 | Pages: 4076

10.3390/jcm13144076 | PMID 39064116 Get It

Objectives: The purpose of this study is to assess the efficacy, short- and long-term cardiovascular and non-cardiovascular mortalities and postoperative morbidities of surgical pulmonary embolectomy (SPE) for patients with massive or submassive pulmonary embolism. Methods: A comprehensive literature review was performed to identify articles reporting SPE for pulmonary embolism. The outcomes included in-hospital and long-term mortality in addition to postoperative morbidities. The random effect inverse variance method was used. Cumulative meta-analysis, leave-one-out sensitivity analysis, subgroup analysis and meta-regression were performed. Results: Among the 1949 searched studies in our systematic literature search, 78 studies met our inclusion criteria, including 6859 cases. The mean age ranged from 42 to 65 years. The percentage of males ranged from 25.6% to 86.7%. The median rate of preoperative cardiac arrest was 27.6%. The percentage of contraindications to preoperative systemic thrombolysis was 30.4%. The preoperative systemic thrombolysis use was 11.5%. The in-hospital mortality was estimated to be 21.96% (95% CI: 19.21–24.98); in-hospital mortality from direct cardiovascular causes was estimated to be 16.05% (95% CI: 12.95–19.73). With a weighted median follow-up of 3.05 years, the late cardiovascular and non-cardiovascular mortality incidence rates were 0.39 and 0.90 per person-year, respectively. The incidence of pulmonary bleeding, gastrointestinal bleeding, surgical site bleeding, non-surgical site bleeding and wound complications was 0.62%, 4.70%, 4.84%, 5.80% and 7.2%, respectively. Cumulative meta-analysis showed a decline in hospital mortality for SPE from 42.86% in 1965 to 20.56% in 2024. Meta-regression revealed that the publication year and male sex were associated with lower in-hospital mortality, while preoperative cardiac arrest, the need for inotropes or vasopressors and preoperative mechanical ventilation were associated with higher in-hospital mortality. Conclusions: This study demonstrates acceptable perioperative mortality rates and late cardiovascular and non-cardiovascular mortality in patients who undergo SPE for massive or submassive pulmonary embolism.
Features of Importance in Nasal Endoscopy: Deriving a Meaningful Framework
Babahaji, Layla M., Ganeshan, Vinayak , Nguyen, Thinh S., Ahmed, Omar G. , Barton, Blair M. , Halawi, Akaber, Joe, Stephanie, Marino, Michael J. , Patel, Zara M. , Rangarajan, Sanjeet V., Riley, Charles A. , Roxbury, Christopher R. , Tabaee, Abtin, Tang, Dennis M. , Wu, Arthur W. , Yim, Michael , Bidwell, Jonathan, Riley, Charles A. , McCoul, Edward D , Patel, Zara , Wu, Arthur W , Chandra, Rakesh Kumar , Chen, Philip G. , Gudis, David A. , Higgins, Thomas S , Kuan, Edward C , Ramakrishnan, Vijay R , McCoul, Edward D.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 5, 2024 | Volume: 171 | Issue: 4 | Pages: 1052-1061

10.1002/ohn.889 | PMID 38967295 Get It

AbstractObjectiveCritical components of the nasal endoscopic examination have not been definitively established for either the normal examination or for clinical disorders. This study aimed to identify concordance among rhinologists regarding the importance of examination findings for various nasal pathologies.Study DesignA consortium of 19 expert rhinologists across the United States was asked to rank the importance of findings on nasal endoscopy for 5 different sinonasal symptom presentations.SettingAn online questionnaire was distributed in July 2023.MethodsThe questionnaire utilized JotForm® software and featured 5 cases with a set of 4 identical questions per case, each covering a common indication for nasal endoscopy. Rankings were synthesized into Normalized Attention Scores (NASs) and Weighted Normalized Attention Scores (W‐NASs) to represent the perceived importance of each feature, scaled from 0 to 1.ResultsGeneral concordance was found for examination findings on nasal endoscopy within each case. The perceived features of importance differed between cases based on clinical presentation. For instance, in evaluating postnasal drip, the middle meatus was selected as the most important structure to examine (NAS, 0.73), with mucus selected as the most important abnormal finding (W‐NAS, 0.66). The primary feature of interest for mucus was whether it was purulent or not (W‐NAS, 0.67). Similar analyses were performed for features in each case.ConclusionThe implicit framework existing among rhinologists may help standardize examinations and improve diagnostic accuracy, augment the instruction of trainees, and inform the development of artificially intelligent algorithms to enhance clinical decision‐making during nasal endoscopy.
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.
Shergill, Ardaman , Liao, Chih-Yi, Baghdadi, Tareq Al, Feldman, Diane, Shroff, Rachna T. , Baghdadi, Tareq Al , Liao, Chih‐Yi , Elsaid, Mohamed I , Ji, Yan , Feldman, Diane, George, Suzanne , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Berg, Stephanie , Schwartz, Gary K. , Münster, Pamela N. , Bekaii‐Saab, Tanios , Abou‐Alfa, Ghassan K. , Shapiro, Geoffrey I.

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS4196-TPS4196

10.1200/jco.2024.42.16_suppl.tps4196 Get It

TPS4196 Background: Advanced BTC patients have poor prognosis. Up to 40% of BTCs have KRAS mutations and are associated with worse overall survival (OS). With a median OS of 7.7 months in KRAS wild-type compared to 1.7 months in KRAS mutated disease, these alterations are independent poor prognostic factors in BTC. Gemcitabine and cisplatin (GC) with or without immunotherapy are often used as 1st-line therapies. However, there is a lack of data on best 2nd-line regimens. mFOLFOX6 (5-fluorouracil [5-FU], leucovorin [LV], oxaliplatin) or liposomal irinotecan+5-FU+LV are options when no biomarkers are found (e.g., MSI-H, BRAFV600E, FGFR-fusions, IDH1-mutation, HER2-overexpression). Prior studies do not demonstrate benefit with MEK inhibitors (MEKi), but none of the studies had biomarker selection. Pre-clinical studies in BTC cell lines suggest synergy between MEKi and 5-FU. Thymidylate synthase (TS )levels induced by 5-FU are downregulated by addition of binimetinib. Early clinical studies show safety and tolerance of this combination. In this study, we will evaluate if the combination of mFOLFOX6+binimetinib improves OS for patients with BTC and MAPK mutations compared to mFOLFOX6 alone in 2nd-line therapy. Methods: EAY191-A6 is a treatment study arm of the NCI ComboMATCH master registration trial EAY191. The A6 trial has a randomized phase II design, enrolling a maximum of 66 patients. Patients with any MAPK pathway mutations except those with available therapies will be eligible. Patient must first enroll to the EAY191 master trial. Local molecular results may be used for enrollment. Submission of tissue at baseline is mandatory. Eligible patients will be randomized 1:1 to mFOLFOX6 vs mFOLFOX6 + binimetinib (45 mg oral twice a day every 14 days). Stratification factors include location and stage of disease. Primary efficacy analysis will compare OS in the intent-to-treat population. If the observed hazard ratio (HR) of experimental arm vs standard of care is < 0.545 (corresponding to an observed increase in OS by 5 months or longer), experimental treatment will be considered superior. An interim futility analysis at 50% of expected events will be conducted. If the observed HR is ≥ 1, experimental treatment will not be considered superior, and accrual maybe suspended. Secondary endpoints include progression-free survival, objective response rate, duration of response, disease control rate and toxicity of treatments. Exploratory objectives include prognostic modeling, correlations of genomic alterations with response or resistance and use of machine learning for outcome prediction. This study is active and open to accrual. Clinical trial information: NCT05564403 .
Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177Lutetium.
Kusne, Yael , Pritzl, Stephanie , Finke, Christy M. , Hobday, Timothy J. , Starr, Jason S. , Orme, Jacob J. , Patnaik, Mrinal M. , Mosalem, Osama , Lasho, Terra L. , Bekaii‐Saab, Tanios , Hálfdánarson, Þorvarður R. , Sonbol, Mohamad Bassam , Childs, Daniel S. , Sartor, Oliver

Mayo Clinic

Journal of Clinical Oncology | July 2, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3020-3020

10.1200/jco.2024.42.16_suppl.3020 Get It

3020 Background: Radioligand therapy (RLT) use has been increasing with the approval of 177Lu-Dotatate for metastatic neuroendocrine tumors (NET) & 177Lu-PSMA-617 for metastatic castration resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasms [tMN, including myelodysplastic syndrome (MDS) & acute myeloid leukemia, (AML)] have been reported after 177Lutetium (177Lu) for NET with rates of 2-20% & median time from first 177Lu to tMN of 2.8yrs [4-12]. Clonal hematopoiesis (CH) is a risk factor for tMN, with the spectrum of CH depending on selection pressures. To describe the prevalence of therapy selected CH & tMN, we performed a retrospective analysis of patients (pts) who had a bone marrow biopsy (BMB) post-177Lu. Methods: After IRB approval, we queried the electronic health record for pts with BMB post-177Lu. Pt demographics, treatment history, labs & BMB results were collected. Results: Fifty-seven pts met criteria, 41 (72%) with NET & 16 (28%) with mCRPC. . Median age at BMB was 68yrs (range, 28-85). Of the 57pts, prior treatments included: radiation (RT) in 21 (37%), temozolomide in 14 (25%), taxane in 15 (26%), & platinum agents in 10 (18%). The median number of 177Lu cycles was 4 (range, 1-11).Cytogenetics were available in 84% (n = 48) & were normal in 60% (n = 29). Of those with abnormal cytogenetics (n = 18, 38%), the most common abnormalities involved chromosome (chr) 7 (n = 12, 26%), chr 5 (n = 7, 15%), chr 20 (n = 5, 11%) and complex karyotypes in 7 (15%), with 3 (17%) of these patients having no mutations. Diagnoses were assessable in 49 (86%) pts: 15 (31%) with undefined cytopeniasand 16 (33%) with tMDS. Metastatic carcinoma was identified in 17 Fifty-one percent (n = 29), at a median of 0.5yrs (range, 0.04-2.6) after hematologic diagnosis. Conclusions: The enrichment of CH involving the DDR pathway in recipients of 177Lu underscores the impact of RLT on bone marrow progenitors.
Applications of Artificial Intelligence in Prostate Cancer Care: A Path to Enhanced Efficiency and Outcomes
Harmon, Stephanie A. , Naqvi, Syed Arsalan Ahmed , Cheng, Liang , Riaz, Irbaz Bin , Cheng, Liang , Chen, Zhijun

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 27, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1200/edbk_438516 | PMID 38935882 Get It

The landscape of prostate cancer care has rapidly evolved. We have transitioned from the use of conventional imaging, radical surgeries, and single-agent androgen deprivation therapy to an era of advanced imaging, precision diagnostics, genomics, and targeted treatment options. Concurrently, the emergence of large language models (LLMs) has dramatically transformed the paradigm for artificial intelligence (AI). This convergence of advancements in prostate cancer management and AI provides a compelling rationale to comprehensively review the current state of AI applications in prostate cancer care. Here, we review the advancements in AI-driven applications across the continuum of the journey of a patient with prostate cancer from early interception to survivorship care. We subsequently discuss the role of AI in prostate cancer drug discovery, clinical trials, and clinical practice guidelines. In the localized disease setting, deep learning models demonstrated impressive performance in detecting and grading prostate cancer using imaging and pathology data. For biochemically recurrent diseases, machine learning approaches are being tested for improved risk stratification and treatment decisions. In advanced prostate cancer, deep learning can potentially improve prognostication and assist in clinical decision making. Furthermore, LLMs are poised to revolutionize information summarization and extraction, clinical trial design and operations, drug development, evidence synthesis, and clinical practice guidelines. Synergistic integration of multimodal data integration and human-AI integration are emerging as a key strategy to unlock the full potential of AI in prostate cancer care.
Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
Debban, Catherine L., Ambalavanan, Amirthagowri , Ghosh, Auyon , Buschur, Kristina L., Ma, Yanlin , George, Elizabeth , Pistenmaa, Carrie L. , Bertoni, Alain G. , Oelsner, Elizabeth C. , Moraes, Theo J. , Jacobs, David R. , Christenson, Stephanie A. , Bhatt, Surya P. , Simons, Elinor , Turvey, Stuart E. , Vameghestahbanati, Motahareh , Bourbeau, Jean , Tan, Wan C. , Gabriel, Stacey , Gupta, Namrata , Woodruff, Prescott G. , Ortega, Victor E. , Bleecker, Eugene R. , Meyers, Deborah A. , Hoffman, Eric A. , Barr, R. Graham, Duan, Qing , Smith, Benjamin M. , George, Elizabeth , Bertoni, Alain G , Oelsner, Elizabeth C , Michos, Erin D , Moraes, Theo J , Bhatt, Surya P , Turvey, Stuart E , Engert, James C , Kirby, Miranda , Tan, Wan C , Woodruff, Prescott G , Subbarao, Padmaja , Rich, Stephen S , Hoffman, Eric A , Cho, Michael H , Bossé, Yohan , Duan, Qingling , Manichaikul, Ani W , Ghosh, Auyon J , Jacobs, David R , Christenson, Stephanie A , Ambalavanan, Amirthagowri , Li, Zhonglin , Michos, Erin D. , Kaner, Robert J. , Rich, Stephen S. , Cho, Michael H. , Bossé, Yohan , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 27, 2024 | Volume: 210 | Issue: 12 | Pages: 1421-1431

10.1164/rccm.202401-0011oc | PMID 38935874 Get It

Abstract Rationale Dysanapsis refers to a mismatch between airway tree caliber and lung size arising early in life. Dysanapsis assessed by computed tomography (CT) is evident by early adulthood and associated with chronic obstructive pulmonary disease (COPD) risk later in life. Objectives By examining the genetic factors associated with CT-assessed dysanapsis, we aimed to elucidate its molecular underpinnings and physiological significance across the lifespan. Methods We performed a genome-wide association study of CT-assessed dysanapsis in 11,951 adults, including individuals from two population-based and two COPD-enriched studies. We applied colocalization analysis to integrate genome-wide association study and gene expression data from whole blood and lung. Genetic variants associated with dysanapsis were combined into a genetic risk score that was applied to examine association with lung function in children from a population-based birth cohort (n = 1,278) and adults from the UKBiobank (n = 369,157). Measurements and Main Results CT-assessed dysanapsis was associated with genetic variants from 21 independent signals in 19 gene regions, implicating HHIP (hedgehog interacting protein), DSP, and NPNT as potential molecular targets based on colocalization of their expression. A higher dysanapsis genetic risk score was associated with obstructive spirometry among 5-year-old children and among adults in the fifth, sixth, and seventh decades of life. Conclusions CT-assessed dysanapsis is associated with variation in genes previously implicated in lung development, and dysanapsis genetic risk is associated with obstructive lung function from early life through older adulthood. Dysanapsis may represent an endophenotype link between the genetic variations associated with lung function and COPD.
GCT-05. UPDATED REPORT ON TREATMENT MODALITIES IN METASTATIC GERMINOMA IN CHILDREN: A MULTI-INSTITUTIONAL ANALYSIS
Thia, Alexia, Su, Jack M., MacDonald, Shannon M. , Perkins, Stephanie M., Govender, Dinisha , Foo, Jen Chun , Rajagopal, Revathi , O’Halloran, Katrina , Sleightholm, Richard, Lafay‐Cousin, Lucie , Cansanay, Rose Daynielle A, Schlosser, Mary-Pat , Cappellano, Andréa Maria , Dassi, Natália , Fisher, Michael J. , Graham, Richard , Baglivo, Sofía Jares, Ronsley, Rebecca , Khan, Sara , Magnum, Ross, Hoffman, Lindsey M. , Knowles, Truman , Mueller, Sabine , Zaghloul, Mohamed S. , Abdelhaleem, Nada A, El‐Ayadi, Moatasem , Abdelbaki, Mohamed S , Shatara, Margaret , Abu-Arja, Mohammad H , Gorsi, Hamza S. , Dholaria, Hetal , Schwartz, Jonathan, Bartels, Ute , Amayiri, Nisreen Yousef , Yılmaz, Yasin , Czogała, Małgorzata , Mastronuzzi, Angela , Michaiel, George

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.260 Get It

Abstract BACKGROUND Primary intracranial germ cell tumors (GCTs) are rare heterogeneous tumors; germinoma accounts for two-thirds of cases. While neoadjuvant chemotherapy followed by response-based reduced radiotherapy dose and field is the established approach for managing localized CNS germinomas, controversy persists regarding the treatment of primary metastatic disease. Additionally, limited research exists on the utilization of neoadjuvant chemotherapy in primary metastatic germinoma. METHODS A retrospective multi-institutional analysis was conducted to assess overall survival (OS) and event-free survival (EFS) among patients diagnosed with metastatic germinoma who were treated with various modalities. RESULTS We identified 88 patients, including 63 males and 25 females. The median age at presentation was 13.5 years. All patients, who had undergone both brain and spine MRIs, had their diagnoses confirmed through a biopsy, positive CSF cytology, and/or positive CSF tumor markers at presentation. Primary Tumor location was pineal (n=37), suprasellar (n=27), bifocal (n=14) and others (n=9). Eight patients underwent subtotal resection. Craniospinal irradiation (CSI; 21-24 Gy) was administered to 71 patients (81%), while eight patients (9%) received whole ventricular irradiation (WVI; 23.4-30 Gy). Whole brain radiation was given to four patients (5%; 24 Gy), and two patients (2%) had unknown fields. Boosts to primary and/or metastatic sites were administered in all but seven patients. Notably, thirty patients (34%) received CSI without neoadjuvant chemotherapy. At the end of therapy, 69 patients had complete response, 10 partial response and the response was unknown in six. Three patients did not receive irradiation, all died of disease progression. The median follow-up was 64 months (range 6-159 months), yielding an OS of 96.6%. Ongoing multi-institutional data collection and analysis will be presented at the meeting. CONCLUSION Our study is one of the largest studies to date in metastatic germinoma and may provide insight into the role of neoadjuvant chemotherapy with lower CSI doses.
Hepatitis B transmission/reactivation associated with Hepatitis B core antibody and Hepatitis C nucleic acid testing positive organs: A report from the Organ Procurement and Transplantation Network Disease Transmission Advisory Committee
Te, Helen S. , Lee, Dong Heun , Woolley, Ann E. , Fisher, Cynthia E. , Sellers, Marty T. , Taimur, Sarah , Livelli, Taylor, Watkins, T. I., Handarova, Dzhuliyana, Berry, Gerald J. , Graves, Riki, Hughart, Anna L., Kittleson, M. , Marboe, Charles C. , Miller, Rachel , Danziger‐Isakov, Lara , Abidi, Maheen Z , Taimur, Sarah , Berry, Gerald J , Trindade, Anil J , Pouch, Stephanie M , Danziger-Isakov, Lara , Te, Helen S , Abidi, Maheen Z. , Watkins, Tamika, Ho, Chak‐Sum , Sharma, Tanvi S. , Wood, R. Patrick, Zaffiri, Lorenzo , Pouch, Stephanie M.

Mayo Clinic

Transplant Infectious Disease | June 17, 2024 | Volume: 26 | Issue: S1 | Pages: No page available

10.1111/tid.14305 | PMID 38881210 Get It

AbstractBackgroundBetter access to direct‐acting antiviral (DAA) therapy has broadened the utilization of hepatitis C virus (HCV) nucleic acid testing (NAT) positive organs with excellent outcomes. However, DAA therapy has been associated with hepatitis B virus (HBV) reactivation.AimTo determine the risk of HBV transmission or reactivation with utilization of HBV core antibody positive (HBcAb+) and HCV NAT positive (HCV+) organs, which presumably required DAA therapy.MethodsThe number of HBcAb+ donors with delineated HCV NAT status was obtained from the Organ Procurement and Transplantation Network (OPTN) database. The number of unexpected HBV infections from transplanted organs adjudicated as “proven” or “probable” transmission was obtained from the OPTN Ad Hoc Disease Transmission Advisory Committee database. A chart review of the donors of “proven” or “probable” cases was conducted.ResultsFrom January 1, 2016, to December 31, 2021, 7735 organs were procured from 3767 HBcAb+ donors and transplanted into 7469 recipients; 545 (14.5%) donors were also HCV+. HBV transmission or reactivation occurred in seven recipients. The rate is not significantly different between recipients of HCV+ (0.18%, 2/1115) and the HCV NAT negative (HCV‐) organs (0.08%, 5/6354) (p = 0.28) or between recipients of HCV+ and HCV‐ livers as well as non‐liver organs. HBV transmission or reactivation occurred within a median of 319 (range, 41–1117) days post‐transplant in the setting of missing, inadequate, or truncated prophylaxis.ConclusionHBV reactivation associated with DAA therapy for HBcAb+ HCV+ organs is less frequent than reported in the non‐transplant population, possibly due to the common use of HBV prophylaxis in the at‐risk transplant population. image
Somatic epimutations cap genetic determinism in the human diploid chromatin epigenome
Vollger, Mitchell R. , Swanson, Elliott , Neph, Shane , Dubocanin, Danilo, Ho, Ching‐Huang , Cheng, Y. H. Hank, Ranchalis, Jane , Munson, Katherine M. , Sedeño-Cortés, Adriana E. , Mudeppa, Devaraja G., Fondrie, William E. , Bohaczuk, Stephanie C. , Dippel, Maxwell A., Mao, Yizi , Parmalee, Nancy L. , Garcia, Gage H. , Meyer, Jeffrey G., Cicek, Mine S., Witten, Daniela , Ray, John , Swanson, Elliott G , Neph, Shane J , Ranchalis, Jane , Munson, Katherine M , Ho, Ching-Huang , Sedeño-Cortés, Adriana E , Fondrie, William E , Bohaczuk, Stephanie C , Mao, Yizi , Mallory, Benjamin J , Harvey, William T , Kwon, Younjun , Garcia, Gage H , Hoekzema, Kendra , Cicek, Mine , Eichler, Evan E , Noble, William S , Bennett, James T , Ray, John P , Stergachis, Andrew B , Dubocanin, Danilo, Cheng, Y. H. Hank, Mudeppa, Devaraja G., Dippel, Maxwell A.

Mayo Clinic

No container title available | June 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.06.14.599122 | PMID 40501892 Get It

Diploid human cells contain two non-identical genomes, and differences in their regulation underlie human development and disease. We present Fiber-seq Inferred Regulatory Elements (FIRE) and show that FIRE provides a more comprehensive and quantitative snapshot of the accessible chromatin landscape across the 6 Gbp diploid human genome, overcoming previously unrecognized biases in existing regulatory element catalogs. FIRE enables comprehensive detection of haplotype-selective chromatin accessibility (HSCA), exposing novel imprinted elements lacking underlying parent-of-origin CpG methylation differences, and gene regulatory modules that permit genes to escape X chromosome inactivation. We uncover that the human leukocyte antigen (HLA) locus harbors the most HSCA in immune cells, where we resolve specific transcription factor (TF) binding events disrupted by disease-associated variants. Finally, we demonstrate that the regulatory landscape of a cell is littered with autosomal somatic chromatin epimutations that are propagated by clonal expansions to create mitotically stable and non-genetically deterministic chromatin alterations.
De novo and inherited monoallelic variants in TUBA4A cause ataxia and spasticity
Benkirane, Mehdi , Bonhomme, Marion , Morsy, Heba , Marelli, Cécilia , Chaussenot, Annabelle , Smedley, Damian , Cipriani, Valentina , Sainte-Agathe, Jean-Madeleine de, Ding, Can, Larrieu, Lise, Vestito, Letizia , Margot, Henri , Ramond, Francis , Castrioto, Anna , Sansa, Emna, Haetty, Aline, Bergougnoux, Anne , Pointaux, Morgane, Ardouin, Olivier , Goethem, Charles Van , Vincent, Marie‐Claire, Hadjivassiliou, Marios , Cossée, Mireille , Rouaud, Tiphaine , Bartsch, Oliver , Wierenga, Klaas J. , Klee, Eric W. , Vandrovcová, Jana , Debant, Anne , Koenig, Michel, Smedley, Damian , Baux, David , Verheijen, Jan , Freeman, William D , Klee, Eric W , Vandrovcova, Jana , Houlden, Henry , Safgren, Stephanie L. , Agathe, Jean‐Madeleine de Sainte , Ding, Can, Lesca, Gaëtan , Sansa, Emna, Giunti, Paola , Freeman, William D. , Houlden, Henry , Koenig, Michel

Mayo Clinic

Brain | June 14, 2024 | Volume: 147 | Issue: 11 | Pages: 3681-3689

10.1093/brain/awae193 | PMID 38884572 Get It

Abstract Alpha-tubulin 4A encoding gene (TUBA4A) has been associated with familial amyotrophic lateral sclerosis and frontotemporal dementia, based on identification of likely pathogenic variants in patients from distinct amyotrophic lateral sclerosis and frontotemporal dementia cohorts. By screening a multicentric French cohort of 448 unrelated probands presenting with cerebellar ataxia, we identified ultra-rare TUBA4A missense variants, all being absent from public databases and predicted pathogenic by multiple in silico tools. In addition, gene burden analyses in the 100 000 Genomes project (100KGP) showed enrichment of TUBA4A rare variants in the inherited ataxia group compared to controls [odds ratio: 57.0847 (10.2−576.7); P = 4.02 ×10−7]. Taken together, we report 12 patients presenting with spasticity and/or cerebellar ataxia and harbouring a predicted pathogenic TUBA4A missense mutation, including five confirmed de novo cases and a mutation previously reported in a large family presenting with spastic ataxia. Cultured fibroblasts from three patients harbouring distinct TUBA4A missense showed significant alterations in microtubule organization and dynamics, providing insight of TUBA4A variants pathogenicity. Our data confirm the identification of a hereditary spastic ataxia disease gene with variable age of onset, expanding the clinical spectrum of TUBA4A associated phenotypes.